Rafael Holdings Q2 net loss widens on consolidation of Cyclo Therapeutic's costs
Overview
U.S. biotechnology firm's fiscal Q2 revenue rose yr/yr but remains modest
Net loss widened to $6.4 mln due to consolidation of Cyclo Therapeutic’s expenses after Cyclo acquisition
Company expects top-line results from pivotal Phase 3 trial in Q3 calendar 2026
Outlook
Company expects to complete 96-week Phase 3 Trappsol Cyclo trial and report top-line results in Q3 2026
Result Drivers
CYLO ACQUISITION IMPACT - Higher net loss and R&D expenses driven by consolidation of Cyclo Therapeutic's costs after March 2025 acquisition
LOWER ADMIN COSTS - General and administrative expenses fell due to reduced payroll and professional fees, partly offset by Cyclo expenses
Company press release: ID:nGNX8L5Qhc
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Product Revenue |
| $125,000 |
|
Q2 Net Income |
| -$6.33 mln |
|
Q2 Operating Income |
| -$6.66 mln |
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
